A collaboration between Brainomix and AstraZeneca has revealed that Brainomix’s AI-powered e-Lung software is more effective at identifying lung fibrosis patients at risk of decline.
Published in the ‘American Journal of Respiratory and Critical Care Medicine’, the study showcased the superior capabilities of Brainomix e-Lung in pinpointing patients most likely to experience progression in Idiopathic Pulmonary Fibrosis (IPF).
Utilizing the innovative weighted reticulovascular score (WRVS), the e-Lung tool was applied to data from AstraZeneca’s Phase 2 clinical trial of tralokinumab in IPF patients. The results demonstrated e-Lung’s potential in enhancing the efficiency of future clinical trials.
Lead author Dr. Peter George highlighted the significance of the findings, stating that WRVS can identify patients at risk of decline in Forced Vital Capacity (FVC) better than traditional measures.
This study builds upon previous research presented at the American Thoracic Society meeting, underscoring the value of e-Lung in predicting outcomes for IPF patients. AstraZeneca’s Dr. Kristoffer Ostridge emphasized the transformative impact of this collaboration on clinical trial design for interstitial lung disease patients.
In recognition of its impact on stroke patient care, Brainomix’s AI-enabled software was endorsed by the National Institute of Health and Care Excellence in February.
